Thrivent Financial for Lutherans Acquires 106,498 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Thrivent Financial for Lutherans grew its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 738.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 120,928 shares of the company’s stock after acquiring an additional 106,498 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Medpace were worth $40,176,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Centaurus Financial Inc. increased its stake in Medpace by 2.0% in the 3rd quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock valued at $505,000 after buying an additional 29 shares during the last quarter. Lindbrook Capital LLC grew its holdings in shares of Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after acquiring an additional 29 shares in the last quarter. HBK Sorce Advisory LLC increased its position in shares of Medpace by 0.5% in the fourth quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company’s stock valued at $1,789,000 after acquiring an additional 29 shares during the last quarter. Assetmark Inc. raised its holdings in Medpace by 20.1% during the fourth quarter. Assetmark Inc. now owns 173 shares of the company’s stock worth $57,000 after acquiring an additional 29 shares in the last quarter. Finally, Proficio Capital Partners LLC boosted its position in Medpace by 4.1% during the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company’s stock valued at $243,000 after purchasing an additional 29 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

Separately, Robert W. Baird upped their price objective on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $381.44.

Medpace Trading Up 1.4 %

MEDP stock opened at $327.47 on Thursday. Medpace Holdings, Inc. has a 1-year low of $302.01 and a 1-year high of $459.77. The business’s 50 day simple moving average is $338.95 and its 200 day simple moving average is $340.25. The firm has a market capitalization of $9.98 billion, a PE ratio of 25.93, a PEG ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.